A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild, Moderate, or Severe Hepatic Insufficiency

Trial Profile

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild, Moderate, or Severe Hepatic Insufficiency

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2014

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 14 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 25 Oct 2013 Planned End Date changed from 1 Mar 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 09 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top